Key result
Staged TEER linked to ~66% lower 1-year mortality versus conservative management.
Why the study?
Previous studies focused on MR or TR individually without comparing long-term effects, and the impact of staged TEER following TAVR remains unclear.
Does staged transcatheter edge-to-edge repair (TEER) reduce mortality in patients with severe multiple valvular heart disease undergoing transcatheter aortic valve replacement?
Cohort (n=2,823)
Yes
Does staged transcatheter edge-to-edge repair (TEER) reduce mortality in patients with severe multiple valvular heart disease undergoing transcatheter aortic valve replacement?
In patients undergoing TAVR, concomitant severe multiple valvular heart disease increases mortality, but staged transcatheter edge-to-edge repair (TEER) significantly improves 1-year and 5-year survival compared to conservative management.
Staged TEER was associated with lower post-TAVR mortality; hypothesis-generating and requires randomized confirmation.
Background Multiple valvular heart disease correlates with poor outcomes following transcatheter aortic valve replacement. Previous studies have focused on mitral regurgitation (MR) or tricuspid regurgitation (TR) individually, without comparing their long‐term effects. The impact of staged transcatheter edge‐to‐edge repair (TEER) remains unclear. We aimed to assess the prevalence and effects of severe multiple valvular heart disease (sMVHD) and evaluate the impact of staged TEER on outcomes. Methods Patients were recruited from 4 transcatheter aortic valve replacement centers. The primary cohort included 2823 patients to evaluate the prevalence of sMVHD. All patients were screened for additional valvular interventions; those undergoing TEER for severe MR (n=147) or TR (n=59) were included. Results Concomitant sMVHD was observed in 369 patients, with 208 having severe MR and 161 having severe TR. The 1‐year mortality rate was higher in patients with sMVHD compared with the overall cohort (9.0 versus 5.2 per 100 person‐years; P <0.01). Severe TR was associated with the highest 1‐year mortality rate, followed by severe MR and no or mild multiple valvular heart disease (13.3 versus 6.4 versus 3.9 per 100 person‐years; P <0.01). This difference persisted over 5 years ( P <0.01). Patients undergoing staged TEER showed a reduced 1‐year mortality rate compared with conservative management (4.1 versus 12.1 per 100 person‐years; P <0.001). This trend continued over 5 years ( P <0.001). Severe TR was independently associated with an increased mortality rate (hazard ratio, 1.79 [95% CI, 1.17–2.74]; P <0.01). Conclusions Persistent sMVHD was associated with an increased mortality rate following transcatheter aortic valve replacement, with severe TR posing a higher risk than severe MR. Staged TEER was associated with improved outcomes and warrants consideration in sMVHD.
No takes yet. Share an insight, caveat, or question.
Al‐Kassou et al. (2025) conducted a cohort in Multiple valvular heart disease in patients undergoing transcatheter aortic valve replacement (n=2,823). Staged transcatheter edge-to-edge repair (TEER) vs. Conservative management was evaluated on 1-year mortality rate (p=<0.001). Staged transcatheter edge-to-edge repair (TEER) reduced the 1-year mortality rate compared with conservative management (4.1 vs 12.1 per 100 person-years; P<0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: